Sotera Health Reports First-Quarter 2024 Results Q1 2024 net revenues increased 12.5% to $248 million, compared to Q1 2023Q1 2024 net income of $6 million or $0.02 per diluted share, compared to net income of $3 million or $0.01 per diluted share in Q1 2023Q1 2024 Adjusted EBITDA(1) increased 13.7% to $112 million, compared to Q1 2023Q1 2024 Adjusted EPS(1) of $0.13 compared to Adjusted EPS of $0.13 in Q1 2023Company reaffirms 2024 outlook CLEVELAND, May 02, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of missi...
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024 BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. Matinas management will host an investment community conference call and webcast to discuss financial...
Lithium Ionic Awarded Water Rights for Bandeira Lithium Project, Minas Gerais, Brazil TORONTO, May 02, 2024 (GLOBE NEWSWIRE) -- Lithium Ionic Corp. (TSXV: LTH; OTCQX: LTHCF; FSE: H3N) (“Lithium Ionic” or the “Company”), is pleased to report that it has received approval to draw water (“Water Rights”) from the local Piauí River for its 100%-owned Bandeira Lithium Project (“Bandeira”) in Minas Gerais, Brazil. The approval granting the right to use local water resources was granted on April 25, 2024, by the Minas Gerais Institute of Water Management (“Instituto Mineiro de Gestão das Águas” ...
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of 2025, both with Phase 1 data in 2025 KT-253 (MDM2) and KT-333 (STAT3) Phase 1 dose escalation studies ongoing with clinical data updates at ASCO and EHA, respectively Well-capitalized with $745 million in cash as of March 31, 2024, and runway into ...
Agios Reports Business Highlights and First Quarter 2024 Financial Results – Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia now expected in Q2 2024 – – Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia in January – – Phase 3 Readouts from Mitapivat RISE UP Study in Sickle Cell Disease, ACTIVATE-KIDS and ACTIVATE KIDS-T in Pediatric PK Deficiency, All Expected by End of 2025 – – PYRUKYND® (Mitapivat) Net Revenue of $...
Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting PITTSBURGH, May 02, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data highlighting the potential of the Company’s HSV-1 based vector platform for back of the eye gene delivery at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held from May 5-9, 2024 in Seattle, Washington. Poster presentation details are as follows: Ti...
Arvinas to Present at Upcoming Investor Conferences NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences: BofA Securities 2024 Healthcare Conference on Tuesday, May 14 at 3:00 p.m. PT in Las Vegas. Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presen...
PyroGenesis Announces 28-Day Lab Strength Tests Achieve Up to 99.56% Above Compressive Strength Target for Green Cement Additive Product Results surpass Portland Cement plus all traditional cement additive blends in pursuit of fly ash replacement in cement. MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- PyroGenesis Canada Inc. () (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company (the “Company” or “PyroGenesis”) that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address envi...
Arqit and SoftIron Partner to sell more secure data center deployments LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (Arqit), a leader in quantum-safe encryption, and SoftIron, the worldwide leader in true private cloud infrastructure announce a partnership to enable customers to make a seamless migration to quantum safe cloud tasks, with a priority focus on the defense sector. Arqit’s quantum-safe products will be available as part of the SoftIron Partner Marketplace alongside other industry-leading solutions. SoftIron has integrated Arqit's Symmeti...
Lee Enterprises reports second quarter Adjusted EBITDA growth and strong digital growth Adjusted EBITDA(1) growth of 5% YOYDigital-only subscription revenue increased 48%(2) with subscriptions up 25%Total Digital Revenue(3) of $71M represented 48% of total revenue DAVENPORT, Iowa, May 02, 2024 (GLOBE NEWSWIRE) -- Lee Enterprises, Incorporated (NASDAQ: LEE), a digital-first subscription platform providing high quality, trusted, local news, information and a major platform for advertising in 73 markets, today reported preliminary second quarter fiscal 2024 financial results(4) for the peri...
Alta Equipment Group Announces Common Stock Dividend LIVONIA, Mich., May 02, 2024 (GLOBE NEWSWIRE) -- Alta Equipment Group Inc. (NYSE: ALTG) (“Alta” or "the Company"), a leading provider of premium material handling, construction and environmental processing equipment and related services, today announced that its Board of Directors approved the quarterly dividend on its common stock in the amount of $0.057 per share. The dividend payment date is May 31, 2024, to shareholders of record at the close of business on May 15, 2024. About Alta Equipment Group Inc.Alta owns and operates one o...
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its first quarter 2024 financial results and provide a business update on Wednesday, May 15, 2024 before market open. The press release will be available on the newsroom section of the Company’s website at . About Perspective Therapeutics, Inc.Perspective Therapeu...
Colliers Reports First Quarter Results Continued growth and resiliency from highly diversified recurring services First quarter operating highlights: Three months ended March 31(in millions of US$, except EPS) 2024 2023 Revenues$1,002.0 $965.9 Adjusted EBITDA (note 1) 108.7 104.6 Adjusted EPS (note 2) 0.77 0.86 GAAP operating earnings 43.3 22.1 GAAP diluted net earnings (loss) per share 0.26 (0.47) TORONTO, May 02, 2024 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (NASDAQ and TSX: CIGI) (“Colliers” or the “Company”) today announced operating and financial resul...
DAVIDsTEA Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results Fiscal 2023 Sales of $60.6 millionNet loss of $13.8 millionAdjusted EBITDA of negative $5.4 millionCash position of $12.6 millionCompany enters into non-binding term sheet for revolving line of credit of up to $12.0 million Q4 Fiscal 2023 Sales of $24.4 millionNet loss of $3.9 millionAdjusted EBITDA of $0.5 million MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- DAVIDsTEA Inc. (TSX-Venture: DTEA) (“DAVIDsTEA” or the “Company”), a leading tea merchant in North America, announced today its fo...
Les Thés DAVIDsTEA publient leurs résultats financiers du quatrième trimestre et de l’exercice 2023 Exercice financier 2023 Ventes de 60,6 M$Perte nette de 13,8 M$BAIIA ajusté d’une somme négative de 5,4 M$Trésorerie de 12,6 M$La Société conclut un accord de modalités de prêt non contraignant pour une ligne de crédit renouvelable d’un montant maximum de 12,0 M$ T4 2023 Ventes de 24,4 M$Perte nette de 3,9 M$BAIIA ajusté de 0,5 M$ MONTRÉAL, 02 mai 2024 (GLOBE NEWSWIRE) -- Les Thés DAVIDsTEA inc. (TSXV : DTEA) (« DAVIDsTEA » ou la « Société »), l’u...
Aya Gold & Silver Announces At-Depth Drill Results at Zgounder Provides Notice of Q1-2024 Results and Conference Call MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to announce high-grade silver drill results from its at-depth drill exploration program at the Zgounder Silver Mine in the Kingdom of Morocco. Key Highlights (all intersections are in core lengths) In the Central Zone from the 1,950m level: hole ZG-SF-24-107 intercepted 1,459 grams per tonne (“g/t”) silver (“Ag”) over 5.5 m...
Axogen, Inc Reports First Quarter 2024 Financial Results ALACHUA, Fla. and TAMPA, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2024. First Quarter Financial Results First quarter revenue was $41.4 million, a 12.9% increase compared to the first quarter of 2023.In the first quarter of 2024, our gross margin increased to 78.8%, up from 77.7%, as reclassified* in the sam...
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss results for the first quarter 2024 and to provide a corporate update. To access the conference call: U.S. callers should dial and international callers should dial approximately five minutes before the call begins.Participants should ask to be c...
Athira Pharma to Participate in Upcoming May Conferences BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May. Sidoti May 2024 Virtual Investor ConferenceFormat: Company PresentationDate and Time: Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET Location: Virtual The Citizens JMP Life Sciences ConferenceFormat: Fireside...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.